

Frederick R Appelbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3276278/publications.pdf>

Version: 2024-02-01

766
papers

55,483
citations

1163

111
h-index

1381

222
g-index

904
all docs

904
docs citations

904
times ranked

24569
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach. <i>Bone Marrow Transplantation</i> , 2021, 56, 305-313.	1.3	3
2	Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 295-298.	3.3	5
3	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	0.6	45
4	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	2.5	28
5	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. <i>Leukemia and Lymphoma</i> , 2021, 62, 1774-1777.	0.6	0
6	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	3.3	28
7	Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101241.	0.7	2
8	Associations between complete remission and 2- to 3-year survival following 7â€‰%+â€‰%3 induction for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1967-1972.	0.6	1
9	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	3.3	51
10	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	0.6	26
11	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	0.8	72
12	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 16-27.	2.3	170
13	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1226-1233.	0.6	24
14	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. <i>Leukemia Research</i> , 2021, 111, 106736.	0.4	3
15	Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101320.	0.7	9
16	Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. <i>Blood</i> , 2021, 138, 337-337.	0.6	0
17	Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report. <i>Blood</i> , 2021, 138, 522-522.	0.6	0
18	A Gentleman and a Scholar: Elihu H. Estey, MD (1946 â€“2021)., 2021, 18, .		0

#	ARTICLE	IF	CITATIONS
19	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 669-672.	1.3	13
20	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020, 34, 1701-1705.	3.3	15
21	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
22	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€“2007 Versus 2013â€“2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	2.0	157
23	Regimenâ€“intensity per countâ€“recovery and hospitalization index: A new tool to assign regimen intensity for AML. <i>Cancer Medicine</i> , 2020, 9, 6515-6523.	1.3	4
24	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. <i>Blood Advances</i> , 2020, 4, 3302-3310.	2.5	11
25	AML-145: Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S185.	0.2	0
26	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	3.3	22
27	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Antiâ€“CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory nonâ€“hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 775-783.	2.0	7
28	A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). <i>Blood Advances</i> , 2020, 4, 1683-1689.	2.5	43
29	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
30	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 611-616.	2.5	21
31	Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. <i>Haematologica</i> , 2020, 105, 1731-1737.	1.7	20
32	Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101109.	0.7	10
33	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019, 78, 29-33.	0.4	2
34	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60â€“75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019, 33, 2599-2609.	3.3	76
35	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S115-S116.	2.0	0
36	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019, 54, 1511-1514.	1.3	1

#	ARTICLE	IF	CITATIONS
37	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	0.6	292
38	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019, 33, 554-558.	3.3	8
39	Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. <i>Leukemia</i> , 2019, 33, 371-378.	3.3	9
40	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
41	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	0.6	5
42	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 721-749.	2.3	314
43	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. <i>Blood</i> , 2019, 134, 291-291.	0.6	3
44	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019, 134, 2691-2691.	0.6	0
45	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. <i>Blood</i> , 2019, 134, 321-321.	0.6	0
46	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019, 134, 2692-2692.	0.6	0
47	Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2018, 67, 17-20.	0.4	23
48	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
49	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018, 32, 2352-2362.	3.3	39
50	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018, 16, 42-52.	0.5	6
51	Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 405-409.	0.7	5
52	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018, 2, 1705-1718.	2.5	16
53	Next-generation sequencing for measuring minimal residual disease in AML. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 473-474.	12.5	4
54	High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 180-180.	0.6	5

#	ARTICLE	IF	CITATIONS
55	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 1018-1018.	0.6	6
56	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 207-207.	0.6	2
57	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018, 132, 1534-1534.	0.6	1
58	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018, 132, 435-435.	0.6	3
59	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. <i>Blood</i> , 2018, 132, 2710-2710.	0.6	1
60	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. <i>Blood</i> , 2018, 132, 1403-1403.	0.6	2
61	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.	0.6	91
62	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 1388-1388.	0.6	0
63	Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. <i>Blood</i> , 2018, 132, 3986-3986.	0.6	0
64	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018, 132, 5255-5255.	0.6	0
65	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , 2018, 132, 3978-3978.	0.6	0
66	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 691-696.	2.0	46
67	Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. <i>Cancer</i> , 2017, 123, 2472-2481.	2.0	13
68	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017, 129, 1763-1767.	0.6	78
69	Early mortality and overall survival of acute myeloid leukemia based on facility type. <i>American Journal of Hematology</i> , 2017, 92, 764-771.	2.0	58
70	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	13.9	1,628
71	Using a Transplant Recipient as a Donor: The Resilience of Multipotent Stem Cells in Humans. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S297.	2.0	0
72	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after Day 14™ without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2717-2719.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
74	Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 320-326.	0.7	17
75	Gemtuzumab ozogamicin for acute myeloid leukemia. <i>Blood</i> , 2017, 130, 2373-2376.	0.6	130
76	Development and Validation of a Novel Acute Myeloid Leukemiaâ€œComposite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	3.4	125
77	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 926-957.	2.3	451
78	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. <i>Journal of Clinical Oncology</i> , 2017, 35, 2745-2753.	0.8	205
79	Measure for Measure: Measuring the Impact of Measuring Residual Disease in Acute Myeloid Leukemia. <i>Journal of Oncology Practice</i> , 2017, 13, 481-483.	2.5	0
80	Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2017, 130, 73-73.	0.6	1
81	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. <i>Blood Advances</i> , 2016, 1, 250-259.	2.5	142
82	Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 365-371.	0.7	5
83	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016, 101, e284-e286.	1.7	18
84	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1319-1323.	2.0	27
85	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508.	0.6	174
86	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. <i>Blood</i> , 2016, 128, 763-773.	0.6	46
87	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	13.9	352
88	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology</i> , the, 2016, 3, e330-e339.	2.2	26
89	Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2092-2099.	2.0	6
90	Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2016, 136, 210-218.	0.7	15

#	ARTICLE	IF	CITATIONS
91	Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. <i>Leukemia Research</i> , 2016, 42, 68-74.	0.4	10
92	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016, 34, 329-336.	0.8	347
93	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166.	0.6	5
94	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. <i>Blood</i> , 2016, 128, 1613-1613.	0.6	6
95	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	0.6	18
96	Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration. <i>Blood</i> , 2016, 128, 285-285.	0.6	4
97	ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial. <i>Blood</i> , 2016, 128, 896-896.	0.6	10
98	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 901-901.	0.6	42
99	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4043-4043.	0.6	0
100	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. <i>Blood</i> , 2016, 128, 2890-2890.	0.6	0
101	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015, 100, e409-e411.	1.7	10
102	Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. <i>Epigenetics</i> , 2015, 10, 526-535.	1.3	22
103	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia and Lymphoma</i> , 2015, 56, 3031-3037.	0.6	9
104	G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2015, 90, 295-300.	2.0	16
105	Reprint of: Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S3-S10.	2.0	5
106	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 373-378.	2.0	30
107	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40
108	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation. <i>American Journal of Clinical Pathology</i> , 2015, 144, 263-270.	0.4	10

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of <i>NPM1</i> Mutations in the Absence of <i>FLT3</i> Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report. <i>Journal of Clinical Oncology</i> , 2015, 33, 1157-1164.	0.8	113
110	Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1258-1264.	0.8	223
111	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e254-e256.	1.7	3
112	Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 331-335.	1.7	24
113	Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 133-140.	0.7	3
114	Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. <i>Cancer</i> , 2015, 121, 2900-2908.	2.0	23
115	Hematopoietic Cell Transplantation after Solid Organ Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2123-2128.	2.0	16
116	Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 4-7.	2.0	83
117	Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 559-564.	2.0	58
118	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. <i>Blood</i> , 2015, 126, 1308-1308.	0.6	7
119	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2569-2569.	0.6	1
120	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with <i>FLT3</i> Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	0.6	104
121	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015, 126, 796-796.	0.6	12
122	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2015, 126, 908-908.	0.6	17
123	Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0118485.	1.1	5
124	Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. <i>Blood</i> , 2015, 126, 3803-3803.	0.6	0
125	A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5502-5502.	0.6	0
126	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Blood</i> , 2015, 126, 2571-2571.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106. <i>Blood</i> , 2015, 126, 2576-2576.	0.6	0
128	Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 173-173.	0.6	0
129	Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. <i>Blood</i> , 2015, 126, 688-688.	0.6	0
130	Indications for Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in the Genomic Era. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e327-e333.	1.8	9
131	Responsibility for Costs Associated With Clinical Trials. <i>Journal of Clinical Oncology</i> , 2014, 32, 3357-3359.	0.8	24
132	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. <i>Leukemia and Lymphoma</i> , 2014, 55, 1523-1532.	0.6	55
133	Alternative donor transplantation for adults with acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 272-277.	0.7	17
134	SWOG 0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 233-237.	1.2	39
135	Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 164, 223-232.	1.2	56
136	Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Leukemia Research and Treatment</i> , 2014, 2014, 1-9.	2.0	63
137	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. <i>Leukemia Research</i> , 2014, 38, 329-333.	0.4	21
138	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 770-775.	2.0	21
139	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
140	Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 164, 245-250.	1.2	27
141	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. <i>British Journal of Haematology</i> , 2014, 166, 375-381.	1.2	1
142	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
143	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	0.8	361
144	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , 2014, 15, 986-996.	5.1	549

#	ARTICLE	IF	CITATIONS
145	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. <i>British Journal of Haematology</i> , 2014, 165, 497-503.	1.2	38
146	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 165, 504-509.	1.2	73
147	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1363-1368.	2.0	54
148	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 123, 2960-2967.	0.6	62
149	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	0.6	83
150	Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. <i>Haematologica</i> , 2014, 99, 322-328.	1.7	79
151	Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. <i>Blood</i> , 2014, 124, 2399-2399.	0.6	4
152	Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants. <i>Blood</i> , 2014, 124, 2579-2579.	0.6	3
153	Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts. <i>Blood</i> , 2014, 124, 2583-2583.	0.6	3
154	Infusion of a Non HLA-Matched Off-the-Shelf Ex Vivo Expanded Cord Blood Progenitor Cell Product Following Myeloablative Cord Blood Transplantation Is Safe, Decreases the Time to Hematopoietic Recovery, and Results in Excellent Overall Survival. <i>Blood</i> , 2014, 124, 46-46.	0.6	13
155	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 679-679.	0.6	8
156	Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014, 124, 796-796.	0.6	83
157	Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia. <i>Blood</i> , 2014, 124, 2375-2375.	0.6	0
158	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5257-5257.	0.6	0
159	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. <i>Blood</i> , 2014, 124, 3676-3676.	0.6	0
160	Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era. <i>Blood</i> , 2014, 124, 948-948.	0.6	1
161	Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 279-284.	0.7	26
162	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013, 2, 26-28.	0.2	2

#	ARTICLE	IF	CITATIONS
163	Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2013, 6, 547-562.	1.0	25
164	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, 3883-3888.	0.8	42
165	Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. <i>Cancer</i> , 2013, 119, 4170-4179.	2.0	37
166	Implementing a Death with Dignity Program at a Comprehensive Cancer Center. <i>New England Journal of Medicine</i> , 2013, 368, 1417-1424.	13.9	102
167	Significance of FAB subclassification of acute myeloid leukemia, NOS in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013, 121, 2424-2431.	0.6	97
168	The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). <i>Leukemia and Lymphoma</i> , 2013, 54, 252-254.	0.6	34
169	A model for prediction of FLT3-ITD and NPM1 (without) Tj ETQq1 1 0.784314 rjB leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 130-132.	1.2	1
170	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 4854-4860.	0.6	546
171	Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. <i>Blood</i> , 2013, 121, 2567-2573.	0.6	120
172	Acute Myeloid Leukemia, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1047-1055.	2.3	135
173	Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. <i>Haematologica</i> , 2013, 98, 114-118.	1.7	21
174	Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report. <i>Blood</i> , 2013, 122, 1315-1315.	0.6	4
175	Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2013, 122, 2133-2133.	0.6	8
176	Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report. <i>Blood</i> , 2013, 122, 2686-2686.	0.6	1
177	Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial. <i>Blood</i> , 2013, 122, 297-297.	0.6	5
178	A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 3333-3333.	0.6	2
179	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013, 122, 356-356.	0.6	11
180	Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3882-3882.	0.6	9

#	ARTICLE	IF	CITATIONS
181	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	0.6	35
182	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013, 122, 3924-3924.	0.6	6
183	Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. <i>Blood</i> , 2013, 122, 3925-3925.	0.6	5
184	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013, 122, 5002-5002.	0.6	1
185	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013, 122, 61-61.	0.6	29
186	Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial. <i>Blood</i> , 2013, 122, 703-703.	0.6	4
187	The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2013, 8, e70812.	1.1	15
188	A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2013, 122, 3926-3926.	0.6	1
189	Proof-Of-Concept Study For Precision Medicine With Chromosome Genomic Array Testing (CGAT) For Drug Sensitivity Screening In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2578-2578.	0.6	0
190	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013, 122, 64-64.	0.6	2
191	NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children's Oncology Group and SWOG. <i>Blood</i> , 2013, 122, 488-488.	0.6	0
192	Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1318-1318.	0.6	0
193	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 1317-1317.	0.6	0
194	Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience. <i>Blood</i> , 2013, 122, 1383-1383.	0.6	0
195	Pursuing the Goal of a Donor for Everyone in Need. <i>New England Journal of Medicine</i> , 2012, 367, 1555-1556.	13.9	32
196	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 739-742.	1.7	29
197	Gemtuzumab Ozogamicin: Time to Resurrect?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3921-3923.	0.8	95
198	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 984-1021.	2.3	236

#	ARTICLE	IF	CITATIONS
199	Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 1401-1404.	1.7	64
200	Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. <i>Blood</i> , 2012, 119, 5591-5598.	0.6	124
201	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2657-2664.	0.6	133
202	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012, 119, 6198-6208.	0.6	273
203	Long-term outcomes after transplantation of HLA-identical related G-CSF α mobilized peripheral blood mononuclear cells versus bone marrow. <i>Blood</i> , 2012, 119, 2675-2678.	0.6	54
204	Blood consult: monosomal karyotype acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5659-5660.	0.6	2
205	E. Donnall Thomas (1920 α 2012). <i>Science</i> , 2012, 338, 1163-1163.	6.0	4
206	Comparative Outcomes of Donor Graft CD34 ⁺ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3194-3201.	0.8	143
207	Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1211-1218.	2.0	167
208	Anti-T Cell Antibodies as Part of the Preparative Regimen in Hematopoietic Cell Transplantation α A Debate. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S111-S115.	2.0	11
209	Improved outcomes with allogeneic hematopoietic cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 465-471.	0.7	5
210	The rule of three in AML induction α is cladribine the answer?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 376-377.	12.5	10
211	Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). <i>Medical Oncology</i> , 2012, 29, 2095-2101.	1.2	19
212	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. <i>Cancer</i> , 2012, 118, 2411-2419.	2.0	27
213	Impact of residual normal metaphases in core binding factor acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 2420-2423.	2.0	6
214	Success of allogeneic marrow transplantation for children with severe aplastic anaemia. <i>British Journal of Haematology</i> , 2012, 158, 120-128.	1.2	23
215	Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given α Intensive α Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). <i>Blood</i> , 2012, 120, 129-129.	0.6	4
216	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1418-1418.	0.6	3

#	ARTICLE	IF	CITATIONS
217	Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.. Blood, 2012, 120, 2489-2489.	0.6	1
218	Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.. Blood, 2012, 120, 2603-2603.	0.6	6
219	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). Blood, 2012, 120, 3535-3535.	0.6	1
220	A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. Blood, 2012, 120, 3584-3584.	0.6	5
221	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Blood, 2012, 120, 4164-4164.	0.6	3
222	Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. Blood, 2012, 120, 592-592.	0.6	9
223	Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2) Tj ETQq1 1 0.784314 rgBT /Over Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2012, 120, 963-963.	0.6	1
224	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. Blood, 2012, 120, 655-655.	0.6	0
225	RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 1278-1278.	0.6	0
226	A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma. Blood, 2012, 120, 811-811.	0.6	0
227	NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2012, 120, 1479-1479.	0.6	0
228	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of "Acute Myeloid Leukemia, Not Otherwise Specified" in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. Blood, 2012, 120, 540-540.	0.6	0
229	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 1924-1924.	0.6	0
230	Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.. Blood, 2012, 120, 2598-2598.	0.6	0
231	Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study. Blood, 2012, 120, 1995-1995.	0.6	0
232	Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF).. Blood, 2012, 120, 2499-2499.	0.6	0
233	Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. Blood, 2012, 120, 3594-3594.	0.6	1
234	A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.. Blood, 2012, 120, 2590-2590.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.. <i>Blood</i> , 2012, 120, 2622-2622.	0.6	0
236	To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 655-62.	0.3	0
237	The role of hematopoietic cell transplantation as therapy for myelodysplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 541-547.	0.7	7
238	Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 341-350.	2.0	95
239	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 908-915.	2.0	113
240	Generic Immunosuppressants in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 285-290.	2.0	12
241	Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1187-1195.	2.0	25
242	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1308-1315.	2.0	17
243	A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1088-1092.	2.0	35
244	Preparative Regimens and Ageism. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1419-1420.	2.0	11
245	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	0.6	544
246	Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 319-330.	2.3	3
247	Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2011, 117, 7185-7185.	0.6	17
248	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. <i>Haematologica</i> , 2011, 96, 914-917.	1.7	34
249	Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. <i>Haematologica</i> , 2011, 96, 631-632.	1.7	10
250	Acute Myeloid Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 280-317.	2.3	56
251	Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011, 155, 182-189.	1.2	81
252	Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. <i>Leukemia Research</i> , 2011, 35, e164-e166.	0.4	4

#	ARTICLE	IF	CITATIONS
253	Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: An opportunity to revisit the controversy regarding cord blood banking for private use. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1009-1012.	0.8	33
254	Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 1190-1197.	0.8	351
255	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. <i>Journal of Clinical Oncology</i> , 2011, 29, 4417-4424.	0.8	287
256	Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes. <i>Blood</i> , 2011, 118, 145-145.	0.6	4
257	Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 156-156.	0.6	33
258	Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. <i>Blood</i> , 2011, 118, 2520-2520.	0.6	2
259	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011, 118, 258-258.	0.6	7
260	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. <i>Blood</i> , 2011, 118, 289-289.	0.6	8
261	Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes. <i>Blood</i> , 2011, 118, 319-319.	0.6	22
262	Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG. <i>Blood</i> , 2011, 118, 3516-3516.	0.6	2
263	Infusion of Off-the-shelf Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML. <i>Blood</i> , 2011, 118, 3640-3640.	0.6	2
264	Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes. <i>Blood</i> , 2011, 118, 665-665.	0.6	2
265	Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 666-666.	0.6	3
266	Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. <i>Blood</i> , 2011, 118, 83-83.	0.6	5
267	Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not. <i>Blood</i> , 2011, 118, 1497-1497.	0.6	0
268	Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2011, 118, 3617-3617.	0.6	0
269	Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy. <i>Blood</i> , 2011, 118, 2594-2594.	0.6	0
270	Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2R β Xenograft and Confer Susceptibility to Cytarabine. <i>Blood</i> , 2011, 118, 579-579.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery. <i>Blood</i> , 2011, 118, 1498-1498.	0.6	0
272	KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report. <i>Blood</i> , 2011, 118, 2510-2510.	0.6	0
273	Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. <i>Blood</i> , 2011, 118, 2555-2555.	0.6	0
274	Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 326-326.	0.6	1
275	DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,. <i>Blood</i> , 2011, 118, 3519-3519.	0.6	0
276	Identification of Differential Methylation Markers Among Cytogenetic Risk Groups of Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1464-1464.	0.6	0
277	A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 663-663.	0.6	2
278	The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2R β Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine + Clofarabine Chemotherapy. <i>Blood</i> , 2011, 118, 1432-1432.	0.6	1
279	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. <i>Blood</i> , 2011, 118, 1446-1446.	0.6	0
280	Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. <i>Blood</i> , 2010, 115, 3869-3878.	0.6	230
281	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010, 116, 5650-5659.	0.6	33
282	Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2010, 115, 1288-1295.	0.6	50
283	Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. <i>Blood</i> , 2010, 116, 4693-4699.	0.6	456
284	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	0.6	2,963
285	Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 48-58.	1.2	26
286	Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 430-434.	1.2	57
287	Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1766-1771.	0.8	187
288	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 2859-2867.	0.8	191

#	ARTICLE	IF	CITATIONS
289	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	0.8	321
290	Lo and behold, a role for lomustine in acute myeloid leukemia?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 619-621.	12.5	2
291	Dose intensity of preparative regimens for acute myeloid leukemia – One-size-fits-all or tailor-made?. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 509-517.	0.7	9
292	Impact of Recipient Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1463-1466.	2.0	40
293	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	13.9	1,335
294	Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.. <i>Blood</i> , 2010, 116, 1671-1671.	0.6	1
295	Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.. <i>Blood</i> , 2010, 116, 1679-1679.	0.6	1
296	Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment. <i>Blood</i> , 2010, 116, 2191-2191.	0.6	11
297	International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. <i>Blood</i> , 2010, 116, 3085-3085.	0.6	5
298	A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). <i>Blood</i> , 2010, 116, 332-332.	0.6	4
299	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. <i>Blood</i> , 2010, 116, 3450-3450.	0.6	1
300	Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. <i>Blood</i> , 2010, 116, 676-676.	0.6	2
301	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. <i>Blood</i> , 2010, 116, 908-908.	0.6	1
302	Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.. <i>Blood</i> , 2010, 116, 1038-1038.	0.6	0
303	Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2010, 116, 3806-3806.	0.6	0
304	Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. <i>Blood</i> , 2010, 116, 924-924.	0.6	1
305	Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study. <i>Blood</i> , 2010, 116, 2737-2737.	0.6	1
306	Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients. <i>Blood</i> , 2010, 116, 758-758.	0.6	0

#	ARTICLE	IF	CITATIONS
307	CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).. Blood, 2010, 116, 1056-1056.	0.6	4
308	Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study. Blood, 2010, 116, 2161-2161.	0.6	0
309	Association of Graft-Versus-Host Disease and Immunosuppressive Treatment with Risks of Recurrent Malignancy and Mortality After Allogeneic Hematopoietic Cell Transplantation. Blood, 2010, 116, 218-218.	0.6	2
310	A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells. Blood, 2010, 116, 2319-2319.	0.6	0
311	Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.. Blood, 2010, 116, 1065-1065.	0.6	1
312	Clinical and Functional Relevance of Interactions Between the Bone Marrow Stromal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells. Blood, 2010, 116, 2756-2756.	0.6	0
313	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. JAMA - Journal of the American Medical Association, 2009, 301, 2349.	3.8	758
314	Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia. Cancer Research, 2009, 69, 185-192.	0.4	23
315	Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129. Pediatric Blood and Cancer, 2009, 53, 1005-1010.	0.8	43
316	Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. British Journal of Haematology, 2009, 147, 207-216.	1.2	57
317	Optimising the conditioning regimen for acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2009, 22, 543-550.	0.7	27
318	Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a Multicenter Phase III Study. Biology of Blood and Marrow Transplantation, 2009, 15, 749-756.	2.0	19
319	Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission: A Matched Cohort Analysis. Biology of Blood and Marrow Transplantation, 2009, 15, 1122-1129.	2.0	54
320	Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia. Clinical Cancer Research, 2009, 15, 4263-4269.	3.2	189
321	Allogeneic hematopoietic cell transplantation after conditioning with 131I anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 2009, 114, 5444-5453.	0.6	161
322	Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood, 2009, 113, 866-874.	0.6	66
323	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood, 2009, 113, 2888-2894.	0.6	115
324	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood, 2009, 113, 3383-3391.	0.6	106

#	ARTICLE	IF	CITATIONS
325	Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. <i>Blood</i> , 2009, 113, 306-308.	0.6	123
326	G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2068-2068.	0.6	14
327	Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3094-3094.	0.6	4
328	Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2009, 114, 345-345.	0.6	4
329	Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009, 114, 536-536.	0.6	24
330	Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).. <i>Blood</i> , 2009, 114, 651-651.	0.6	15
331	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009, 114, 662-662.	0.6	5
332	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 790-790.	0.6	124
333	Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 3391-3391.	0.6	0
334	Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. <i>Blood</i> , 2009, 114, 4332-4332.	0.6	0
335	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009, 114, 2658-2658.	0.6	1
336	Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.. <i>Blood</i> , 2009, 114, 1035-1035.	0.6	0
337	Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML). <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 85-92.	0.7	24
338	What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 667-675.	0.7	19
339	Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 531-537.	2.0	45
340	Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 799-806.	2.0	23
341	Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: Yesterday, Today, and Tomorrow. <i>Journal of Clinical Oncology</i> , 2008, 26, 2927-2929.	0.8	17
342	Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. <i>Blood</i> , 2008, 111, 2563-2572.	0.6	191

#	ARTICLE	IF	CITATIONS
343	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. <i>Blood</i> , 2008, 111, 4813-4816.	0.6	17
344	Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. <i>Blood</i> , 2008, 111, 2261-2268.	0.6	31
345	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 149-149.	0.6	4
346	The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).. <i>Blood</i> , 2008, 112, 1952-1952.	0.6	3
347	Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2964-2964.	0.6	1
348	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008, 112, 3253-3253.	0.6	4
349	Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). <i>Blood</i> , 2008, 112, 49-49.	0.6	4
350	Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. <i>Blood</i> , 2008, 112, 858-858.	0.6	5
351	Decreased Relapse Rates without Excessive Transplant Related Mortality Following Cord Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants.. <i>Blood</i> , 2008, 112, 968-968.	0.6	2
352	Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2008, 112, 1130-1130.	0.6	0
353	Adult Cord Blood Transplantation (CBT) Vs. Unrelated Donor Transplantation: A Cost Comparison. <i>Blood</i> , 2008, 112, 2383-2383.	0.6	0
354	Hematopoietic-Cell Transplantation at 50. <i>New England Journal of Medicine</i> , 2007, 357, 1472-1475.	13.9	390
355	High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults ≥ 60 Years Old With Relapsed or Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1396-1402.	0.8	112
356	Benchmarks in Clinical Productivity: A National Comprehensive Cancer Network Survey. <i>Journal of Oncology Practice</i> , 2007, 3, 2-8.	2.5	13
357	Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. <i>Journal of Clinical Oncology</i> , 2007, 25, 793-798.	0.8	371
358	Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. <i>Blood</i> , 2007, 109, 2791-2793.	0.6	210
359	The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 1782-1789.	0.6	126
360	End points to establish the efficacy of new agents in the treatment of acute leukemia. <i>Blood</i> , 2007, 109, 1810-1816.	0.6	83

#	ARTICLE	IF	CITATIONS
361	Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. <i>Blood</i> , 2007, 109, 2999-3006.	0.6	107
362	CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. <i>Blood</i> , 2007, 109, 4168-4170.	0.6	176
363	Karying about karyotyping in adult ALL. <i>Blood</i> , 2007, 109, 3127-3127.	0.6	0
364	Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	0.6	292
365	Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage Dysplasia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 345-354.	2.0	50
366	Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 355-365.	2.0	174
367	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. <i>Blood</i> , 2007, 109, 5136-5142.	0.6	287
368	Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007, 25, 799-804.	0.8	320
369	Comorbidity and Disease Status-Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4246-4254.	0.8	380
370	Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 67-75.	0.7	19
371	Graft-Versus-Host Disease: A Surge of Developments. <i>PLoS Medicine</i> , 2007, 4, e198.	3.9	22
372	Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500). <i>American Journal of Hematology</i> , 2007, 82, 1056-1062.	2.0	26
373	Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.. <i>Blood</i> , 2007, 110, 1403-1403.	0.6	1
374	Outcome of Hematopoietic Cell Transplant from HLA-Matched Siblings Compared to a Volunteer Unrelated Donors Matched for HLA-A, B, C, DRB1, and DQB1 Alleles.. <i>Blood</i> , 2007, 110, 170-170.	0.6	1
375	Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.. <i>Blood</i> , 2007, 110, 330-330.	0.6	4
376	Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).. <i>Blood</i> , 2007, 110, 440-440.	0.6	4
377	Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. <i>Blood</i> , 2007, 110, 1077-1077.	0.6	2
378	Outcomes in the Recent Seattle Cord Blood Experience: Low TRM and Relapse; High Mild Acute GVHD and CMV Reactivation.. <i>Blood</i> , 2007, 110, 2019-2019.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. Blood, 2007, 110, 3029-3029.	0.6	2
380	Inhibition of α v β 3 Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells.. Blood, 2007, 110, 4805-4805.	0.6	0
381	Hematopoietic cell transplantation in first complete remission versus early relapse. Best Practice and Research in Clinical Haematology, 2006, 19, 333-339.	0.7	24
382	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. Biology of Blood and Marrow Transplantation, 2006, 12, 573-584.	2.0	88
383	Improving the Efficacy of Reduced Intensity Allogeneic Transplantation for Lymphoma using Radioimmunotherapy. Biology of Blood and Marrow Transplantation, 2006, 12, 697-702.	2.0	36
384	131I α anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood, 2006, 107, 2184-2191.	0.6	146
385	Age and acute myeloid leukemia. Blood, 2006, 107, 3481-3485.	0.6	1,152
386	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. British Journal of Haematology, 2006, 135, 165-173.	1.2	223
387	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. Blood, 2006, 108, 2324-2324.	0.6	3
388	Frequent PML-RAR Δ Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.. Blood, 2006, 108, 2342-2342.	0.6	1
389	A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. Blood, 2006, 108, 316-316.	0.6	10
390	Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.. Blood, 2006, 108, 494-494.	0.6	2
391	Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.. Blood, 2006, 108, 566-566.	0.6	7
392	Conventional and Pretargeted Radioimmunotherapy Using an Anti-Murine CD45 Monoclonal Antibody in a Syngeneic, Disseminated Murine Leukemia Model.. Blood, 2006, 108, 570-570.	0.6	2
393	Changes in the Pattern of Cytogenetic Aberrations with Advancing Age in Acute Myeloid (Non-APL) Leukemia: A Southwest Oncology Study (S9007).. Blood, 2006, 108, 808-808.	0.6	0
394	Lack of Utility of Chimerism Studies at Day 80 after Myeloablative Hematopoietic Cell Transplantation for Acute Lymphocytic Leukemia.. Blood, 2006, 108, 2959-2959.	0.6	0
395	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood, 2005, 105, 49-53.	0.6	376
396	Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood, 2005, 105, 1348-1354.	0.6	105

#	ARTICLE	IF	CITATIONS
397	Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. <i>Blood</i> , 2005, 105, 3749-3756.	0.6	79
398	Increased AF1q gene expression in high-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2005, 128, 218-220.	1.2	26
399	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005, 104, 1442-1452.	2.0	429
400	Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older. <i>Journal of Clinical Oncology</i> , 2005, 23, 3439-3446.	0.8	120
401	A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 465-471.	2.0	78
402	Innovations in preparative regimens for autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 40-42.	2.0	0
403	A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 495-505.	2.0	115
404	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 713-720.	2.0	70
405	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005, 106, 397-397.	0.6	19
406	A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 487-487.	0.6	5
407	Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.. <i>Blood</i> , 2005, 106, 546-546.	0.6	22
408	Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival.. <i>Blood</i> , 2005, 106, 2365-2365.	0.6	0
409	Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.. <i>Blood</i> , 2005, 106, 405-405.	0.6	1
410	Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005, 106, 894-894.	0.6	0
411	Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. <i>Clinical Cancer Research</i> , 2005, 11, 787-94.	3.2	9
412	Targeted Busulfan and Cyclophosphamide as Compared to Busulfan and TBI as Preparative Regimens for Transplantation in Patients with Advanced MDS or Transformation to AML. <i>Leukemia and Lymphoma</i> , 2004, 45, 2409-2418.	0.6	27
413	Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. <i>Leukemia Research</i> , 2004, 28, 1177-1180.	0.4	49
414	Immunobiologic therapies for myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 653-661.	0.7	6

#	ARTICLE	IF	CITATIONS
415	Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 320-327.	2.0	142
416	Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 552-560.	2.0	59
417	The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. <i>Blood</i> , 2004, 103, 4276-4284.	0.6	87
418	Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. <i>Blood</i> , 2004, 103, 347-352.	0.6	225
419	Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the ATRA Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.. <i>Blood</i> , 2004, 104, 394-394.	0.6	5
420	131I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.. <i>Blood</i> , 2004, 104, 813-813.	0.6	2
421	A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004, 104, 828-828.	0.6	2
422	Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.. <i>Blood</i> , 2004, 104, 567-567.	0.6	1
423	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003, 120, 281-288.	1.2	90
424	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 1017-1025.	1.2	42
425	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 472-481.	2.0	75
426	Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. <i>Blood</i> , 2003, 101, 2521-2528.	0.6	139
427	The Current Status of Hematopoietic Cell Transplantation. <i>Annual Review of Medicine</i> , 2003, 54, 491-512.	5.0	125
428	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2003, 102, 3912-3918.	0.6	255
429	Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. <i>Blood</i> , 2003, 101, 3628-3634.	0.6	189
430	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454.	0.6	382
431	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826.	0.6	190
432	High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003, 102, 2351-2357.	0.6	187

#	ARTICLE	IF	CITATIONS
433	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. <i>Blood</i> , 2003, 102, 31-35.	0.6	168
434	Predictors of relapse and overall survival in Philadelphia chromosome[ndash]positive acute lymphoblastic leukemia after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 206-212.	2.0	64
435	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. <i>Blood</i> , 2002, 100, 1201-1207.	0.6	278
436	Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. <i>Blood</i> , 2002, 99, 2002-2008.	0.6	117
437	High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002, 99, 3158-3162.	0.6	205
438	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002, 100, 48-51.	0.6	263
439	A humanized non- α 1FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2002, 99, 2712-2719.	0.6	166
440	Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. <i>Blood</i> , 2002, 100, 3869-3876.	0.6	170
441	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002, 100, 4298-4302.	0.6	427
442	Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2002, 100, 29-35.	0.6	86
443	Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 206-212.	2.0	63
444	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 415-419.	0.6	403
445	Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2002, 43, 1409-1414.	0.6	19
446	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 161-169.	2.0	66
447	Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2002, 20, 3878-3884.	0.8	167
448	Hematopoietic Cell Transplantation as a Form of Immunotherapy. <i>International Journal of Hematology</i> , 2002, 75, 222-227.	0.7	9
449	PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. <i>Leukemia Research</i> , 2002, 26, 91-106.	0.4	42
450	Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. <i>Blood</i> , 2002, 100, 1910-2.	0.6	20

#	ARTICLE	IF	CITATIONS
451	Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: The experience in four centers. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 39-45.	2.0	150
452	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 163-170.	2.0	26
453	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	0.6	1,306
454	Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers. <i>New England Journal of Medicine</i> , 2001, 344, 175-181.	13.9	905
455	Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2134-2141.	0.8	79
456	Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2001, 19, 3611-3621.	0.8	139
457	Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 3244-3254.	0.8	837
458	SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 2001, 72, 1924-1929.	0.5	168
459	Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. <i>Blood</i> , 2001, 98, 988-994.	0.6	200
460	Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. <i>Blood</i> , 2001, 97, 3380-3389.	0.6	356
461	Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2001, 97, 2180-2181.	0.6	64
462	Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. <i>Blood</i> , 2001, 97, 2541-2548.	0.6	96
463	Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2001, 98, 3212-3220.	0.6	393
464	Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. <i>Blood</i> , 2001, 98, 3505-3512.	0.6	119
465	Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. <i>Blood</i> , 2001, 98, 3868-3870.	0.6	64
466	Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. <i>Blood</i> , 2001, 98, 586-593.	0.6	70
467	The significance of bcr-abl molecular detection in chronic myeloid leukemia patients ≥18 months or more after transplantation. <i>Blood</i> , 2001, 98, 1701-1707.	0.6	137
468	FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. <i>Blood</i> , 2001, 97, 3589-3595.	0.6	388

#	ARTICLE	IF	CITATIONS
469	Haematopoietic cell transplantation as immunotherapy. <i>Nature</i> , 2001, 411, 385-389.	13.7	382
470	Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. <i>Leukemia Research</i> , 2001, 25, 23-32.	0.4	22
471	Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). <i>Experimental Hematology</i> , 2001, 29, 448-457.	0.2	211
472	Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial. <i>Cancer Investigation</i> , 2001, 19, 603-610.	0.6	40
473	Stem-Cell Transplantation for Myelofibrosis. <i>New England Journal of Medicine</i> , 2001, 344, 775-776.	13.9	13
474	Hemopoietic stem cell transplantation for myelodysplastic syndrome. <i>Current Opinion in Oncology</i> , 2000, 12, 116-120.	1.1	14
475	Three-color versus four-color multiparameter cell cycle analyses of primary acute myeloid leukemia samples. , 2000, 42, 83-94.		11
476	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 318-328.	1.5	51
477	Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. <i>Leukemia Research</i> , 2000, 24, 481-486.	0.4	16
478	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. <i>Leukemia Research</i> , 2000, 24, 567-574.	0.4	58
479	Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2000, 24, 653-663.	0.4	34
480	A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2000, 24, 183-187.	0.4	20
481	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996.	0.6	122
482	Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1750-1757.	13.9	939
483	Second allogeneic transplantation after failure of first autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 272-279.	2.0	89
484	A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 25-34.	2.0	72
485	Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 321-326.	2.0	32
486	Dedication - Dr. E. Donnall Thomas. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 75-76.	2.0	0

#	ARTICLE	IF	CITATIONS
487	A phase I/II trial of iodine-131 ¹²⁵ tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	0.6	173
488	Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 1999, 94, 1237-1247.	0.6	284
489	A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. <i>Leukemia Research</i> , 1999, 23, 787-794.	0.4	79
490	Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 155-161.	2.0	15
491	Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 289-301.	2.3	63
492	Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. <i>Leukemia Research</i> , 1998, 22, 221-239.	0.4	36
493	Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1998, 338, 962-968.	13.9	602
494	Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 1998, 339, 1649-1656.	13.9	569
495	Myelodysplasia and myeloproliferative disorders. <i>Current Opinion in Hematology</i> , 1997, 4, 261-267.	1.2	6
496	All-trans-Retinoic Acid in Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 1997, 337, 1021-1028.	13.9	1,006
497	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235.	0.6	358
498	Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. <i>British Journal of Haematology</i> , 1997, 98, 1010-1016.	1.2	66
499	Long-term survival after chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 1997, 80, 2199-2204.	2.0	43
500	Long-term survival after chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 1997, 80, 2199-2204.	2.0	22
501	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	0.6	3
502	The role of radioimmunotherapy in bone marrow transplantation. <i>Current Opinion in Hematology</i> , 1996, 3, 438-445.	1.2	8
503	The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 1996, 46, 142-164.	157.7	56
504	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. <i>British Journal of Haematology</i> , 1996, 92, 699-706.	1.2	48

#	ARTICLE	IF	CITATIONS
505	Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1996, 93, 59-67.	1.2	114
506	The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation. <i>Stem Cells</i> , 1996, 14, 261-273.	1.4	49
507	The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation. <i>Oncologist</i> , 1996, 1, 371-380.	1.9	31
508	Targeted therapy for hematologic malignancies: has its promise been realized? Editorial review. <i>Current Opinion in Hematology</i> , 1995, 2, 235-239.	1.2	0
509	Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995, 90, 266-273.	1.2	32
510	Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: A southwest oncology group study. <i>American Journal of Hematology</i> , 1995, 48, 228-232.	2.0	2
511	Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: A Phase I/II trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 1103-1109.	0.4	39
512	Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: A Southwest Oncology Group Study (SWOG-8612). <i>Leukemia Research</i> , 1995, 19, 381-388.	0.4	28
513	Effects of vitamin a on survival in patients with chronic myelogenous leukemia: A SWOG randomized trial. <i>Leukemia Research</i> , 1995, 19, 605-612.	0.4	24
514	Allogeneic marrow transplantation and the use of hematopoietic growth factors. <i>Stem Cells</i> , 1995, 13, 344-350.	1.4	21
515	An Update on Allogeneic Marrow Transplantation for Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 1995, 17, 95-99.	0.6	41
516	Availability and Appropriateness of Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia in 10 Countries. <i>New England Journal of Medicine</i> , 1994, 331, 1063-1067.	13.9	51
517	Post therapy imaging in high dose I-131 radioimmunotherapy patients. <i>Medical Physics</i> , 1994, 21, 1157-1162.	1.6	13
518	Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. <i>Cancer</i> , 1994, 74, 715-721.	2.0	7
519	Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A southwest oncology group study. <i>Hematological Oncology</i> , 1994, 12, 75-85.	0.8	11
520	^{131}I -IRRADIATION OF PRETRANSPLANT BLOOD TRANSFUSIONS FROM UNRELATED DONORS PREVENTS SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DOG LEUKOCYTE ANTIGEN-IDENTICAL CANINE MARROW GRAFTS. <i>Transplantation</i> , 1994, 57, 423-426.	0.5	32
521	The use of colony stimulating factors in marrow transplantation. <i>Cancer</i> , 1993, 72, 3387-3392.	2.0	14
522	Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. <i>British Journal of Haematology</i> , 1993, 85, 182-184.	1.2	9

#	ARTICLE	IF	CITATIONS
523	Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support. <i>New England Journal of Medicine</i> , 1993, 329, 1219-1224.	13.9	599
524	STUDIES OF THE USE OF L-LEUCYL-L-LEUCINE METHYL ESTER IN CANINE ALLOGENEIC MARROW TRANSPLANTATION. <i>Transplantation</i> , 1993, 55, 1244-1249.	0.5	9
525	FK-506 AND METHOTREXATE PREVENT GRAFT-VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN-NONIDENTICAL DONORS. <i>Transplantation</i> , 1993, 56, 800-807.	0.5	53
526	THE USE OF RADIOLABELED ANTI-CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA. <i>Transplantation</i> , 1992, 54, 829-833.	0.5	153
527	TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH A NONMITOGENIC ANTI-CD3 MONOCLONAL ANTIBODY. <i>Transplantation</i> , 1992, 54, 844-850.	0.5	55
528	SUCCINYL ACETONE PLUS METHOTREXATE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN DLA-HAPLOIDENTICAL CANINE LITTERMATE MARROW GRAFTS. <i>Transplantation</i> , 1992, 54, 947.	0.5	3
529	A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. <i>British Journal of Haematology</i> , 1992, 80, 49-54.	1.2	35
530	Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer. <i>New England Journal of Medicine</i> , 1991, 324, 1773-1778.	13.9	481
531	THE SOMATOSTATIN ANALOG OCTREOTIDE IN THE MANAGEMENT OF THE SECRETORY DIARRHEA OF THE ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE IN A PATIENT AFTER BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1990, 49, 1194-1195.	0.5	30
532	Biotherapy after marrow transplantation and the use of hematopoietic growth factors. <i>Current Opinion in Oncology</i> , 1990, 2, 289-296.	1.1	2
533	A PHASE I-II STUDY EVALUATING THE MURINE ANTI-IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE. <i>Transplantation</i> , 1990, 50, 49-61.	0.5	53
534	Inadvertent Transmission of a Donor's Acute Myeloid Leukemia in Bone Marrow Transplantation for Chronic Myelocytic Leukemia. <i>New England Journal of Medicine</i> , 1990, 322, 1794-1796.	13.9	90
535	Immunomodulatory and Antimicrobial Efficacy of Intravenous Immunoglobulin in Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 1990, 323, 705-712.	13.9	394
536	Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. <i>American Journal of Medicine</i> , 1990, 89, 134-136.	0.6	44
537	Bone marrow transplantation in canine GM1 gangliosidosis. <i>Clinical Genetics</i> , 1990, 38, 274-280.	1.0	22
538	Bone Marrow Transplantation for Patients with Myelodysplasia. <i>Annals of Internal Medicine</i> , 1990, 112, 590.	2.0	125
539	Graft-versus-Host Disease as Adoptive Immunotherapy in Patients with Advanced Hematologic Neoplasms. <i>New England Journal of Medicine</i> , 1989, 320, 828-834.	13.9	336
540	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989, 72, 567-572.	1.2	95

#	ARTICLE	IF	CITATIONS
541	Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia or Lymphoma. <i>New England Journal of Medicine</i> , 1989, 320, 197-204.	13.9	652
542	Marrow transplantation in the treatment of patients with lymphoma. <i>Current Opinion in Oncology</i> , 1989, 1, 47-54.	1.1	3
543	FAILURE OF ANTI-Ia MONOCLONAL ANTIBODY TO ABROGATE TRANSFUSION-INDUCED SENSITIZATION AND PREVENT MARROW GRAFT REJECTION IN DLA-IDENTICAL CANINE LITTERMATES. <i>Transplantation</i> , 1988, 45, 505.	0.5	5
544	ALLOGENEIC BONE MARROW TRANSPLANTATION IN IRRADIATED ADULT RABBITS. <i>Transplantation</i> , 1987, 44, 351-354.	0.5	4
545	FACILITATION OF ENGRAFTMENT OF DLA-NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION. <i>Transplantation</i> , 1987, 44, 607-613.	0.5	26
546	ENGRAFTMENT OF DLA-NONIDENTICAL BONE MARROW FACILITATED BY RECIPIENT TREATMENT WITH ANTI-CLASS II MONOCLONAL ANTIBODY AND METHOTREXATE. <i>Transplantation</i> , 1987, 44, 340-345.	0.5	8
547	Bone marrow transplantation for malignant lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1987, 23, 263-266.	0.9	12
548	Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy?. <i>British Journal of Haematology</i> , 1987, 67, 261-266.	1.2	2
549	Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy?. <i>British Journal of Haematology</i> , 1987, 67, 261-266.	1.2	6
550	VENOCLUSIVE DISEASE OF THE LIVER AFTER CHEMORADIOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION1. <i>Transplantation</i> , 1987, 43, 870-873.	0.5	2
551	CURE OF MALIGNANT LYMPHOMA IN DOGS WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. <i>Transplantation</i> , 1986, 42, 19-22.	0.5	38
552	INTERSTITIAL PNEUMONITIS FOLLOWING AUTOLOGOUS BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1986, 42, 515-517.	0.5	107
553	Cyclic neutropenia as a premalignant manifestation of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1986, 22, 9-16.	2.0	12
554	Selection of patients with hodgkin's disease and non-hodgkin's lymphoma for bone marrow transplantation. <i>International Journal of Cell Cloning</i> , 1986, 4, 94-106.	1.6	15
555	Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia. <i>New England Journal of Medicine</i> , 1986, 314, 729-735.	13.9	1,353
556	TREATMENT OF HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE WITH ANTITHYMOCYTE GLOBULIN AND CYCLOSPORINE WITH OR WITHOUT METHYLPREDNISOLONE. <i>Transplantation</i> , 1985, 40, 162-166.	0.5	70
557	MARROW TRANSPLANT STUDIES IN DOGS WITH MALIGNANT LYMPHOMA. <i>Transplantation</i> , 1985, 39, 499-503.	0.5	28
558	Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. <i>Leukemia Research</i> , 1985, 9, 1255-1261.	0.4	40

#	ARTICLE	IF	CITATIONS
559	Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft-versus-host disease. <i>Medical and Pediatric Oncology</i> , 1985, 13, 165-172.	1.0	69
560	Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. <i>Cancer</i> , 1985, 55, 2202-2209.	2.0	29
561	Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. <i>American Journal of Medicine</i> , 1985, 78, 978-983.	0.6	73
562	Allogeneic Marrow Transplantation in the Treatment of Preleukemia. <i>Annals of Internal Medicine</i> , 1984, 100, 689.	2.0	95
563	Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapy. <i>Hematological Oncology</i> , 1984, 2, 151-168.	0.8	70
564	COMBINED IMMUNOSUPPRESSION WITH CYCLOSPORINE AND METHOTREXATE IN DOGS GIVEN BONE MARROW GRAFTS FROM DLA-HAPLOIDENTICAL LITTERMATES. <i>Transplantation</i> , 1984, 37, 62-64.	0.5	47
565	Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia. <i>Annals of Internal Medicine</i> , 1984, 101, 581.	2.0	185
566	Chronic myelogenous leukemia: Prolonged survival with spontaneous decline in the frequency of Ph1-positive cells and subsequent development of mixed Ph1-positive and Ph1-negative blast crisis. <i>Cancer</i> , 1983, 51, 149-153.	2.0	17
567	Treatment of Hairy-Cell Leukemia with Chemoradiotherapy and Identical-Twin Bone-Marrow Transplantation. <i>New England Journal of Medicine</i> , 1982, 307, 479-481.	13.9	71
568	Treatment of Chronic Granulocytic Leukemia with Chemoradiotherapy and Transplantation of Marrow from Identical Twins. <i>New England Journal of Medicine</i> , 1982, 306, 63-68.	13.9	138
569	NONBACTERIAL NONFUNGAL PNEUMONIA FOLLOWING MARROW TRANSPLANTATION IN 100 IDENTICAL TWINS. <i>Transplantation</i> , 1982, 33, 265-268.	0.5	110
570	Prolonged complete remission following high dose chemotherapy of burkitt's lymphoma in relapse. <i>Cancer</i> , 1978, 41, 1059-1063.	2.0	156
571	STUDY OF CELL DOSE AND STORAGE TIME ON ENGRAFTMENT OF CRYOPRESERVED AUTOLOGOUS BONE MARROW IN A CANINE MODEL. <i>Transplantation</i> , 1978, 26, 245-248.	0.5	63
572	⁶⁷ Ga Radionuclide Imaging in Burkitt's Lymphoma. <i>Radiology</i> , 1975, 117, 639-645.	3.6	24
573	Autologous Graft-vs.-Host Disease. , 0, , 405-413.		0
574	Biology of Hematopoietic Stem and Progenitor Cells. , 0, , 69-95.		3
575	Radiotherapeutic Principles of Hematopoietic Cell Transplantation. , 0, , 333-350.		0
576	Immune Reconstitution Following Hematopoietic Cell Transplantation. , 0, , 222-231.		1

#	ARTICLE	IF	CITATIONS
577	The Pathophysiology of Graft-Versus-Host Disease. , 0, , 208-221.		2
578	A History of Allogeneic Hematopoietic Cell Transplantation. , 0, , 1-7.		7
579	Uses and Growth of Hematopoietic Cell Transplantation. , 0, , 15-21.		14
580	The History of Autologous Hematopoietic Cell Transplantation. , 0, , 8-14.		8
581	Expansion of Hematopoietic Stem Cells. , 0, , 88-101.		1
582	Molecular Biology of Stem Cell Renewal. , 0, , 64-71.		0
583	Biology of Hematopoietic Stem and Progenitor Cells. , 0, , 36-63.		1
584	Mechanisms of Tolerance. , 0, , 188-207.		0
585	Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation. , 0, , 102-115.		0
586	Cellular Biology of Hematopoiesis. , 0, , 72-87.		0
587	Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 845-859.		0
588	Hematopoietic Cell Transplantation for Immunodeficiency Diseases. , 0, , 1430-1442.		3
589	Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells. , 0, , 118-129.		1
590	Preparative Regimens and Modification of Regimen-Related Toxicities. , 0, , 158-177.		1
591	T-Cell Depletion to Prevent Graft-vs.-Host Disease. , 0, , 221-233.		3
592	Antibody Mediated Purging. , 0, , 244-253.		1
593	Uses and Growth of Hematopoietic Cell Transplantation. , 0, , 9-15.		10
594	Mechanisms of Tolerance. , 0, , 300-323.		3

#	ARTICLE	IF	CITATIONS
595	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases. , 0, , 324-343.		1
596	Murine Models for Graft-Vs.-Host Disease. , 0, , 344-352.		2
597	The Pathophysiology of Graft-Vs.-Host Disease. , 0, , 353-368.		18
598	Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 16-30.		1
599	Hematopoietic Cell Donors. , 0, , 538-549.		4
600	Fungal Infections After Hematopoietic Cell Transplantation. , 0, , 683-700.		2
601	Cytomegalovirus Infection. , 0, , 701-726.		4
602	Herpes Simplex Virus Infections. , 0, , 727-731.		1
603	Epstein-Barr Virus Infection. , 0, , 749-756.		1
604	Gastrointestinal and Hepatic Complications. , 0, , 769-810.		3
605	Immunological Reconstitution Following Hematopoietic Cell Transplantation. , 0, , 853-861.		5
606	Growth and Development After Hematopoietic Cell Transplantation. , 0, , 929-943.		4
607	Secondary Malignancies After Hematopoietic Cell Transplantation. , 0, , 962-977.		3
608	Allogeneic Transplantation for Myelodysplastic and Myeloproliferative Disorders. , 0, , 1084-1095.		1
609	Hematopoietic Cell Transplantation from Unrelated Donors. , 0, , 1132-1149.		1
610	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 1262-1282.		1
611	Hematopoietic Cell Transplantation for Neuroblastoma. , 0, , 1333-1344.		1
612	Nutrition Support of the Hematopoietic Cell Transplant Recipient. , 0, , 1551-1569.		3

#	ARTICLE	IF	CITATIONS
613	Oral Complications of Hematopoietic Cell Transplantation. , 0, , 1589-1607.		7
614	Growth and Development after Hematopoietic Cell Transplantation. , 0, , 1608-1619.		9
615	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation. , 0, , 1620-1637.		4
616	Neurologic Complications of Hematopoietic Cell Transplantation. , 0, , 1653-1663.		3
617	Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients. , 0, , 1664-1670.		2
618	Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect. , 0, , 176-187.		4
619	The Human Graft-versus-Tumor Response“ and How to Exploit It. , 0, , 232-247.		1
620	Dendritic Cells in Hematopoietic Cell Transplantation. , 0, , 248-263.		1
621	Pharmacologic Basis for High-dose Chemotherapy. , 0, , 287-315.		4
622	High-dose Preparatory Regimens. , 0, , 316-332.		3
623	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation. , 0, , 365-375.		1
624	Pathology of Hematopoietic Cell Transplantation. , 0, , 390-405.		1
625	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. , 0, , 443-460.		3
626	Psychosocial Issues in Hematopoietic Cell Transplantation. , 0, , 488-501.		2
627	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients. , 0, , 502-514.		1
628	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries. , 0, , 544-558.		4
629	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy. , 0, , 590-604.		3
630	Hematopoietic Cell Transplantation from Unrelated Donors. , 0, , 675-691.		3

#	ARTICLE	IF	CITATIONS
631	Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia. , 0 , 761-774.		3
632	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. , 0 , 791-805.		1
633	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children. , 0 , 806-826.		1
634	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders. , 0 , 827-844.		2
635	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 0 , 897-913.		1
636	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies. , 0 , 1043-1058.		5
637	Hematopoietic Cell Transplantation for Immunodeficiency Diseases. , 0 , 1105-1124.		1
638	Hematopoietic Cell Transplantation for Storage Diseases. , 0 , 1136-1162.		3
639	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation. , 0 , 1226-1243.		3
640	Vascular Access and Complications. , 0 , 1244-1256.		1
641	Pharmacologic Prevention of Acute Graft-Versus-Host Disease. , 0 , 1257-1274.		6
642	Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy. , 0 , 1304-1324.		8
643	Fungal Infections after Hematopoietic Cell Transplantation. , 0 , 1346-1366.		5
644	Cytomegalovirus Infection. , 0 , 1367-1381.		5
645	Herpes Simplex Virus Infections. , 0 , 1382-1387.		6
646	Varicella-zoster Virus Infections. , 0 , 1388-1409.		5
647	Gastrointestinal and Hepatic Complications. , 0 , 1434-1455.		18
648	Kidney and Bladder Complications of Hematopoietic Cell Transplantation. , 0 , 1473-1486.		4

#	ARTICLE	IF	CITATIONS
649	In Utero Transplantation. , 0, , 577-589.		1
650	Histocompatibility. , 0, , 145-162.		1
651	Nursing Role in Hematopoietic Cell Transplantation. , 0, , 461-477.		2
652	Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma. , 0, , 1207-1220.		2
653	Hematopoietic Cell Transplantation for Storage Diseases. , 0, , 1455-1470.		3
654	Outcomes Research in Hematopoietic Cell Transplantation. , 0, , 428-441.		1
655	A History of Bone Marrow Transplantation. , 0, , 1-8.		3
656	Methods for Gene Transfer: Genetic Manipulation of Hematopoietic Stem Cells. , 0, , 107-117.		0
657	AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy. , 0, , 1369-1384.		0
658	Hematopoietic Cell Transplantation for Sickle Cell Disease. , 0, , 1417-1429.		0
659	Hematopoietic Cell Transplantation for Osteopetrosis. , 0, , 1443-1454.		0
660	Hematopoietic Cell Transplantation for Macrophage and Granulocyte Disorders. , 0, , 1471-1482.		0
661	Hematopoietic Cell Transplantation in the 21st Century. , 0, , 1505-1510.		0
662	Pharmacologic Basis for High-Dose Chemotherapy. , 0, , 130-157.		0
663	Radiotherapeutic Principles of Hematopoietic Cell Transplantation. , 0, , 178-197.		1
664	Pharmacology and the Use of Immunosuppressive Agents After Hematopoietic Cell Transplantation. , 0, , 209-220.		0
665	Pharmacologic Purging of Bone Marrow. , 0, , 254-257.		1
666	Molecular Inhibition of Gene Expression in Hematopoietic Cells. , 0, , 258-271.		0

#	ARTICLE	IF	CITATIONS
667	The Detection and Significance of Minimal Residual Disease. , 0 , 272-285.		0
668	Pathology of Hematopoietic Cell Transplantation. , 0 , 286-299.		0
669	Graft-Vs.-Tumor Responses. , 0 , 369-379.		2
670	Adoptive Immunotherapy With Antigen-Specific T Cells. , 0 , 380-404.		1
671	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation. , 0 , 447-462.		0
672	Clinical and Administrative Support for Hematopoietic Cell Transplant Programs. , 0 , 463-468.		2
673	Nursing Issues in Hematopoietic Cell Transplantation. , 0 , 469-482.		0
674	The Patient's Perspective. , 0 , 483-487.		0
675	Ethical Issues in Hematopoietic Cell Transplantation. , 0 , 488-496.		0
676	Psychosocial Issues in Hematopoietic Cell Transplantation. , 0 , 497-506.		2
677	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients. , 0 , 507-518.		0
678	Histocompatibility. , 0 , 31-42.		0
679	Sexuality After Hematopoietic Cell Transplantation. , 0 , 519-528.		0
680	Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation. , 0 , 529-537.		0
681	In Utero Transplantation. , 0 , 565-575.		1
682	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High-Dose Cancer Therapy. , 0 , 576-587.		2
683	Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation. , 0 , 588-598.		0
684	Cryopreservation of Hematopoietic Cells. , 0 , 599-612.		0

#	ARTICLE	IF	CITATIONS
685	Recombinant Growth Factors After Hematopoietic Cell Transplantation. , 0 , 613-623.		0
686	Hematopoietic Cell Donor Registries. , 0 , 624-631.		1
687	Functional Evolution of the Major Histocompatibility Complex. , 0 , 43-52.		0
688	Varicella-Zoster Virus Infections. , 0 , 732-748.		1
689	Neurological Complications of Hematopoietic Cell Transplantation. , 0 , 811-823.		0
690	The Hematopoietic Microenvironment. , 0 , 53-61.		0
691	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation. , 0 , 833-852.		0
692	Vaccination of Hematopoietic Cell Transplant Recipients. , 0 , 862-872.		0
693	Pulmonary Complications After Hematopoietic Cell Transplantation. , 0 , 873-882.		1
694	Nutritional Support of Hematopoietic Cell Recipients. , 0 , 883-893.		1
695	Oral Complications. , 0 , 911-928.		1
696	Molecular Aspects of Stem Cell Renewal. , 0 , 62-68.		0
697	Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia. , 0 , 979-1001.		3
698	Allogeneic Transplantation for Paroxysmal Nocturnal Hemoglobinuria. , 0 , 1002-1006.		0
699	Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia. , 0 , 1018-1024.		0
700	Allogeneic Hematopoietic Cell Transplantation for Adult Patients With Acute Myeloid Leukemia. , 0 , 1025-1039.		2
701	Allogeneic Transplantation for Acute Myeloid Leukemia in Children. , 0 , 1040-1054.		0
702	Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. , 0 , 1055-1066.		0

#	ARTICLE	IF	CITATIONS
703	Allogeneic Transplantation for Acute Lymphoblastic Leukemia in Children. , 0 , 1067-1083.		1
704	Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. , 0 , 1096-1104.		0
705	Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia. , 0 , 1105-1115.		1
706	Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors. , 0 , 1116-1131.		3
707	Management of Relapse After Allogeneic Transplantation. , 0 , 1150-1163.		0
708	Allogeneic Hematopoietic Cell Transplantation for Solid Tumors. , 0 , 1177-1187.		1
709	Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease. , 0 , 1189-1206.		0
710	Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. , 0 , 1221-1237.		0
711	Expansion of Hematopoietic Stem Cells. , 0 , 96-106.		0
712	Autologous Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. , 0 , 1238-1249.		0
713	Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. , 0 , 1250-1261.		0
714	Autologous Hematopoietic Cell Transplantation for AL Amyloidosis. , 0 , 1283-1297.		0
715	Hematopoietic Cell Transplantation for Breast Cancer. , 0 , 1298-1307.		1
716	Hematopoietic Cell Transplantation in Germ Cell Tumors. , 0 , 1308-1319.		0
717	Hematopoietic Cell Transplantation in Ovarian Carcinoma. , 0 , 1320-1332.		0
718	Hematopoietic Cell Transplantation for Brain Tumors. , 0 , 1345-1353.		0
719	Hematopoietic Cell Transplantation for Pediatric Patients With Solid Tumors. , 0 , 1354-1368.		1
720	Genetic Manipulation of Hematopoietic Stem Cells. , 0 , 116-128.		0

#	ARTICLE	IF	CITATIONS
721	Critical Care of the Hematopoietic Cell Transplant Recipient. , 0 , 1539-1550.		0
722	Secondary Malignancies after Hematopoietic Cell Transplantation. , 0 , 1638-1652.		0
723	Hematopoietic Cell Transplantation in the Future. , 0 , 1671-1676.		0
724	Overview of Hematopoietic Cell Transplantation Immunology. , 0 , 129-144.		0
725	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation. , 0 , 163-175.		0
726	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases. , 0 , 264-285.		1
727	Radioimmunotherapy and Hematopoietic Cell Transplantation. , 0 , 351-364.		0
728	The Detection and Significance of Minimal Residual Disease. , 0 , 376-389.		0
729	Biostatistical Methods in Hematopoietic Cell Transplantation. , 0 , 406-427.		0
730	Ethical Issues in Hematopoietic Cell Transplantation. , 0 , 478-487.		0
731	Sexuality Following Hematopoietic Cell Transplantation: An Important Health-related Quality of Life Issue. , 0 , 515-525.		0
732	Hematopoietic Cell Transplantation: The Patient's Perspective. , 0 , 526-532.		0
733	Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation. , 0 , 533-543.		0
734	Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Embryonic Stem Cells. , 0 , 23-35.		0
735	Removal of Tumor Cells from the Hematopoietic Graft. , 0 , 605-617.		0
736	Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation. , 0 , 618-630.		0
737	Cryopreservation of Hematopoietic Cells. , 0 , 631-644.		0
738	Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation. , 0 , 645-656.		0

#	ARTICLE	IF	CITATIONS
739	Donor Selection for Hematopoietic Cell Transplantation. , 0, , 692-703.		0
740	Hematopoietic Cell Transplantation for Aplastic Anemia. , 0, , 705-726.		0
741	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria. , 0, , 727-733.		0
742	Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia. , 0, , 751-760.		0
743	Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia. , 0, , 775-790.		0
744	Hematopoietic Cell Transplantation for Hodgkin's Disease. , 0, , 860-877.		0
745	Non-Hodgkin's Lymphoma. , 0, , 878-896.		0
746	Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis. , 0, , 914-930.		0
747	Hematopoietic Cell Transplantation for Breast Cancer. , 0, , 931-947.		0
748	Hematopoietic Cell Transplantation in Germ Cell Tumors. , 0, , 948-957.		0
749	Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors. , 0, , 958-959.		0
750	Hematopoietic Cell Transplantation for Neuroblastoma. , 0, , 970-984.		0
751	Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors. , 0, , 985-1000.		0
752	Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection. , 0, , 1001-1013.		0
753	Hematopoietic Cell Transplantation for Autoimmune Diseases. , 0, , 1014-1029.		1
754	Hematopoietic Cell Transplantation for Rare Hematologic Malignancies. , 0, , 1030-1042.		0
755	Management of Relapse after Hematopoietic Cell Transplantation. , 0, , 1059-1075.		0
756	Hematopoietic Cell Transplantation for Thalassemia. , 0, , 1077-1089.		0

#	ARTICLE	IF	CITATIONS
757	Hematopoietic Cell Transplantation for Sickle Cell Disease. , 0, , 1090-1104.		0
758	Hematopoietic Cell Transplantation for Osteopetrosis. , 0, , 1125-1135.		1
759	Hematopoietic Cell Transplantation for Macrophage and Granulocyte Disorders. , 0, , 1163-1177.		0
760	Hematopoietic Cell Transplantation for Fanconi's Anemia. , 0, , 1178-1199.		0
761	Mechanisms and Treatment of Graft Failure. , 0, , 1201-1218.		0
762	Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation. , 0, , 1219-1225.		0
763	T-Cell Depletion to Prevent Graft-versus-Host Disease. , 0, , 1275-1286.		0
764	Epstein-Barr Virus Infection. , 0, , 1410-1418.		0
765	Endocrine Complications Following Hematopoietic Cell Transplantation. , 0, , 1487-1522.		0
766	Common Potential Drug Interactions Following Hematopoietic Cell Transplantation. , 0, , 1523-1538.		0